These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 31433119

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate.
    Zhang W, Zang N, Jiang Y, Chen P, Wang X, Zhang X.
    Sci Rep; 2015 Dec 10; 5():17888. PubMed ID: 26657792
    [Abstract] [Full Text] [Related]

  • 3. Caspase-3/CPP32 immunoreactivity and its correlation with frequency of apoptotic bodies in human prostatic carcinomas and benign nodular hyperplasias.
    Sohn JH, Kim DH, Choi NG, Park YE, Ro JY.
    Histopathology; 2000 Dec 10; 37(6):555-60. PubMed ID: 11122438
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia.
    Lee LM, Pan CC, Cheng CJ, Chi CW, Liu TY.
    Anticancer Res; 2001 Dec 10; 21(2B):1291-4. PubMed ID: 11396201
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia.
    Zenzmaier C, Sampson N, Pernkopf D, Plas E, Untergasser G, Berger P.
    Endocrinology; 2010 Aug 10; 151(8):3975-84. PubMed ID: 20555034
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
    Matos AR, Coutinho-Camillo CM, Thuler LC, Fonseca FP, Soares FA, Silva EA, Gimba ER.
    Exp Mol Pathol; 2013 Jun 10; 94(3):438-44. PubMed ID: 23470460
    [Abstract] [Full Text] [Related]

  • 10. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.
    Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, Comeglio P, Santi R, Filippi S, Sebastianelli A, Nesi G, Serni S, Carini M, Maggi M.
    Prostate; 2013 Sep 10; 73(13):1391-402. PubMed ID: 23765639
    [Abstract] [Full Text] [Related]

  • 11. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract.
    Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, Marini M, Gacci M, Vannelli GB, Sandner P, Maggi M.
    J Sex Med; 2010 Jan 10; 7(1 Pt 1):59-69. PubMed ID: 19796053
    [Abstract] [Full Text] [Related]

  • 12. The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions.
    Levakov AF, Kaćanski MM, Vucković N, Zivojinov M, Amidzić J, Sabo JI.
    Vojnosanit Pregl; 2015 Oct 10; 72(10):906-13. PubMed ID: 26665557
    [Abstract] [Full Text] [Related]

  • 13. Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer.
    Sinha AA, Quast BJ, Wilson MJ, Fernandes ET, Reddy PK, Ewing SL, Sloane BF, Gleason DF.
    Prostate; 2001 Sep 15; 48(4):274-84. PubMed ID: 11536307
    [Abstract] [Full Text] [Related]

  • 14. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.
    Wang C.
    Curr Opin Urol; 2010 Jan 15; 20(1):49-54. PubMed ID: 19887943
    [Abstract] [Full Text] [Related]

  • 15. Apoptosis and nuclear shapes in benign prostate hyperplasia and prostate adenocarcinoma: comparison with and relation to Gleason score.
    Choi NG, Sohn JH, Park HW, Jung TY.
    Int J Urol; 1999 Jan 15; 6(1):13-8. PubMed ID: 10221859
    [Abstract] [Full Text] [Related]

  • 16. Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate.
    Willman JH, Holden JA.
    Prostate; 2000 Mar 01; 42(4):280-6. PubMed ID: 10679757
    [Abstract] [Full Text] [Related]

  • 17. Higher expression of phosphodiesterase type 5 in the anterior fibromuscular stroma of the human prostate.
    Iwata T, Fujihara A, Shiraishi T, Yamada Y, Hongo F, Ukimura O.
    World J Urol; 2020 Nov 01; 38(11):2915-2921. PubMed ID: 31996980
    [Abstract] [Full Text] [Related]

  • 18. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate.
    Lee HK, Driscoll D, Asch H, Asch B, Zhang PJ.
    Prostate; 1999 Jun 15; 40(1):14-9. PubMed ID: 10344719
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.